JP2002504325A - 転写因子ｓｔａｔ１と転写因子ｕｓｆ１の間の結合を阻害する能力をもつ化合物のスクリーニング方法 - Google Patents
転写因子ｓｔａｔ１と転写因子ｕｓｆ１の間の結合を阻害する能力をもつ化合物のスクリーニング方法Info
- Publication number
- JP2002504325A JP2002504325A JP2000532511A JP2000532511A JP2002504325A JP 2002504325 A JP2002504325 A JP 2002504325A JP 2000532511 A JP2000532511 A JP 2000532511A JP 2000532511 A JP2000532511 A JP 2000532511A JP 2002504325 A JP2002504325 A JP 2002504325A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- expression
- nucleic acid
- acid sequence
- stat1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000006381 STAT1 Transcription Factor Human genes 0.000 title claims abstract description 65
- 108010044012 STAT1 Transcription Factor Proteins 0.000 title claims abstract description 65
- 101000671637 Homo sapiens Upstream stimulatory factor 1 Proteins 0.000 title claims abstract description 49
- 230000027455 binding Effects 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 41
- 150000001875 compounds Chemical class 0.000 title claims abstract description 31
- 230000002401 inhibitory effect Effects 0.000 title description 2
- 238000012216 screening Methods 0.000 title 1
- 102100040105 Upstream stimulatory factor 1 Human genes 0.000 claims abstract description 49
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 44
- 229920001184 polypeptide Polymers 0.000 claims abstract description 42
- 230000001747 exhibiting effect Effects 0.000 claims abstract description 10
- 230000014509 gene expression Effects 0.000 claims description 81
- 150000007523 nucleic acids Chemical group 0.000 claims description 56
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 51
- 108010074328 Interferon-gamma Proteins 0.000 claims description 39
- 102000008070 Interferon-gamma Human genes 0.000 claims description 39
- 229940044627 gamma-interferon Drugs 0.000 claims description 38
- 108091035710 E-box Proteins 0.000 claims description 30
- 102100026371 MHC class II transactivator Human genes 0.000 claims description 27
- 102000004127 Cytokines Human genes 0.000 claims description 24
- 108090000695 Cytokines Proteins 0.000 claims description 24
- 230000004913 activation Effects 0.000 claims description 20
- 230000006698 induction Effects 0.000 claims description 15
- 108700008625 Reporter Genes Proteins 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 3
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 2
- 108060001084 Luciferase Proteins 0.000 claims 2
- 239000005089 Luciferase Substances 0.000 claims 2
- 102000006635 beta-lactamase Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 description 53
- 210000004027 cell Anatomy 0.000 description 41
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 description 30
- 108700002010 MHC class II transactivator Proteins 0.000 description 21
- 238000001994 activation Methods 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 101150076359 Mhc gene Proteins 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- -1 for example Proteins 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 3
- 108700011215 E-Box Elements Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 229940028885 interleukin-4 Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 101150111062 C gene Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 108010005636 polypeptide C Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100033029 Carbonic anhydrase-related protein 11 Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101100321669 Fagopyrum esculentum FA02 gene Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 101000867841 Homo sapiens Carbonic anhydrase-related protein 11 Proteins 0.000 description 1
- 101000855520 Homo sapiens Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 101001075218 Homo sapiens Gastrokine-1 Proteins 0.000 description 1
- 101000837845 Homo sapiens Transcription factor E3 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000671649 Homo sapiens Upstream stimulatory factor 2 Proteins 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 244000048927 Lolium temulentum Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 101710188313 Protein U Proteins 0.000 description 1
- 101710149894 Protein usf Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100028507 Transcription factor E3 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100040103 Upstream stimulatory factor 2 Human genes 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009146 cooperative binding Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000008866 synergistic binding Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR98/02025 | 1998-02-19 | ||
| FR9802025A FR2775003A1 (fr) | 1998-02-19 | 1998-02-19 | Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1 |
| PCT/FR1999/000376 WO1999042571A1 (fr) | 1998-02-19 | 1999-02-19 | Methode de criblage de composes capables d'inhiber la fixation entre le facteur de transcription stat1 et le facteur de transcription usf1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002504325A true JP2002504325A (ja) | 2002-02-12 |
| JP2002504325A5 JP2002504325A5 (https=) | 2006-04-13 |
Family
ID=9523151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000532511A Pending JP2002504325A (ja) | 1998-02-19 | 1999-02-19 | 転写因子ｓｔａｔ１と転写因子ｕｓｆ１の間の結合を阻害する能力をもつ化合物のスクリーニング方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6379894B1 (https=) |
| EP (1) | EP1068310B1 (https=) |
| JP (1) | JP2002504325A (https=) |
| AU (1) | AU2431299A (https=) |
| DE (1) | DE69938450T2 (https=) |
| FR (1) | FR2775003A1 (https=) |
| WO (1) | WO1999042571A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10148886A1 (de) | 2001-10-04 | 2003-04-30 | Avontec Gmbh | Inhibition von STAT-1 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09500026A (ja) * | 1994-04-14 | 1997-01-07 | リガンド・ファーマシューティカルズ・インコーポレーテッド | サイトカインに応答性のｄｎａスペーサー調節要素およびその使用方法 |
| WO1997002354A1 (en) * | 1995-06-30 | 1997-01-23 | Medical Research Council | INTERACTION OF p53 WITH TRANSCRIPTION FACTOR DP-1 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5976835A (en) * | 1992-03-19 | 1999-11-02 | The Rockefeller University | Nucleic acids encoding receptor recognition factor Stat1α and Stat1β, and methods of use thereof |
| DE69429608T2 (de) | 1993-08-26 | 2002-09-12 | Novimmune Sa, Genf/Geneve | MHC-Klasse-II Transaktivator (CIITA) und dessen Anwendungen |
| US5463023A (en) * | 1993-10-22 | 1995-10-31 | Washington University | Composition for inhibition of intracellular transcription |
| JPH09511908A (ja) * | 1994-04-14 | 1997-12-02 | リガンド・ファーマシューティカルズ・インコーポレイテッド | サイトカインに応答性のｄｎａ調節要素 |
| US5814517A (en) * | 1994-04-14 | 1998-09-29 | Ligand Pharmaceuticals, Inc. | DNA spacer regulatory elements responsive to cytokines and methods for their use |
| US5707803A (en) * | 1994-04-14 | 1998-01-13 | Ligand Pharmaceuticals, Inc. | DNA regulatory elements responsive to cytokines and methods for their use |
| US5672473A (en) | 1994-08-24 | 1997-09-30 | President And Fellows Of Harvard College | Methods of identifying compounds useful for treating autoimmune diseases |
| US5643726A (en) * | 1994-11-10 | 1997-07-01 | The General Hospital Corporation | Methods for modulating transcription from the amyloid β-protein precursor (APP) promoter |
| US5716622A (en) * | 1995-01-06 | 1998-02-10 | The Rockefeller University | Functionally active regions of signal transducer and activators of transcription |
| US5821053A (en) * | 1995-02-10 | 1998-10-13 | Center For Blood Research, Inc. | LIL-Stat DNA binding sites and methods for identifying inhibitory binding agents |
| ZA97476B (en) * | 1996-01-22 | 1998-07-21 | Res Dev Foundation | Novel methods for the characterization of compounds which stimulate STF-1 expression in pancreatic islet cells. |
| FR2762327B1 (fr) * | 1997-04-22 | 1999-07-02 | Transgene Sa | Sequence d'acide nucleique de genes ciita, susceptibles d'etre impliquees dans le controle et la regulation de l'expression de genes codant pour des molecules mhc de type ii et leur utilisation, notamment comme medicament |
| US6207391B1 (en) * | 1998-03-31 | 2001-03-27 | Tularik Inc. | High-throughput screening assays for modulators of STAT4 and STAT6 activity |
| US6235873B1 (en) * | 1999-07-31 | 2001-05-22 | The Rockefeller University | Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes |
-
1998
- 1998-02-19 FR FR9802025A patent/FR2775003A1/fr active Pending
-
1999
- 1999-02-19 AU AU24312/99A patent/AU2431299A/en not_active Abandoned
- 1999-02-19 DE DE69938450T patent/DE69938450T2/de not_active Expired - Fee Related
- 1999-02-19 JP JP2000532511A patent/JP2002504325A/ja active Pending
- 1999-02-19 WO PCT/FR1999/000376 patent/WO1999042571A1/fr not_active Ceased
- 1999-02-19 EP EP99903787A patent/EP1068310B1/fr not_active Expired - Lifetime
-
2000
- 2000-08-18 US US09/641,999 patent/US6379894B1/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09500026A (ja) * | 1994-04-14 | 1997-01-07 | リガンド・ファーマシューティカルズ・インコーポレーテッド | サイトカインに応答性のｄｎａスペーサー調節要素およびその使用方法 |
| WO1997002354A1 (en) * | 1995-06-30 | 1997-01-23 | Medical Research Council | INTERACTION OF p53 WITH TRANSCRIPTION FACTOR DP-1 |
Non-Patent Citations (1)
| Title |
|---|
| JPN6009013765, Ｉｍｍｕｎｉｔｙ, 19980201, Ｖｏｌ．８, ｐ．１５７−１６６ * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1068310B1 (fr) | 2008-04-02 |
| WO1999042571A1 (fr) | 1999-08-26 |
| DE69938450T2 (de) | 2009-05-07 |
| US6379894B1 (en) | 2002-04-30 |
| EP1068310A1 (fr) | 2001-01-17 |
| FR2775003A1 (fr) | 1999-08-20 |
| DE69938450D1 (de) | 2008-05-15 |
| WO1999042571A8 (fr) | 1999-11-18 |
| AU2431299A (en) | 1999-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Manna et al. | Assessment of the role of activator protein-1 on transcription of the mouse steroidogenic acute regulatory protein gene | |
| Cvekl et al. | A Complex Array of Positive and Negative Elements Regulates the Chicken αΑ-Crystallin Gene: Involvement of Pax-6, USF, CREB and/or CREM, and AP-1 Proteins | |
| Bayne et al. | Increased expression of the FIGLA transcription factor is associated with primordial follicle formation in the human fetal ovary | |
| Bucher et al. | Expression of the troponin complex genes: transcriptional coactivation during myoblast differentiation and independent control in heart and skeletal muscles | |
| US5866323A (en) | Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors | |
| Oshima | Werner syndrome | |
| Gebara et al. | Protein-DNA interactions associated with the onset of testisspecific expression of the mammalian Pgk-2 gene | |
| Flink et al. | Alternatively processed isoforms of cellular nucleic acid-binding protein interact with a suppressor region of the human β-myosin heavy chain gene | |
| JP2001512698A (ja) | 新規な老化因子遺伝子ｐ２３の単離 | |
| Abe et al. | Structure, expression, and chromosomal localization of the human gene encoding a germinal center-associated nuclear protein (GANP) that associates with MCM3 involved in the initiation of DNA replication | |
| US20090023152A1 (en) | Transcription factor MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances | |
| Spicuglia et al. | TCRα enhancer activation occurs via a conformational change of a pre‐assembled nucleo‐protein complex | |
| US5840832A (en) | Transcription factor regulating MHC expression, CDNA and genomic clones encoding same and retroviral expression constructs thereof | |
| Hewetson et al. | Identification of the RUSH consensus-binding site by cyclic amplification and selection of targets: demonstration that RUSH mediates the ability of prolactin to augment progesterone-dependent gene expression | |
| Bruno et al. | Upstream stimulatory factor but not c-Myc enhances transcription of the human polymeric immunoglobulin receptor gene | |
| Proietti et al. | Heregulin co-opts PR transcriptional action via Stat3 role as a coregulator to drive cancer growth | |
| US5807740A (en) | Regulators of UCP2 gene expression | |
| Jiang et al. | Gαq-PKD/PKCμ signal regulating the nuclear export of HDAC5 to induce the IκB expression and limit the NF-κB-mediated inflammatory response essential for early pregnancy | |
| Higuchi et al. | Cyclic AMP enhances the expression of an extravillous trophoblast marker, melanoma cell adhesion molecule, in choriocarcinoma cell JEG3 and human chorionic villous explant cultures | |
| JP2002504325A (ja) | 転写因子ｓｔａｔ１と転写因子ｕｓｆ１の間の結合を阻害する能力をもつ化合物のスクリーニング方法 | |
| Reim et al. | The RRM protein NonA from Drosophila forms a complex with the RRM proteins Hrb87F and S5 and the Zn finger protein PEP on hnRNA | |
| Yang et al. | Id1 induces apoptosis through inhibition of RORgammat expression | |
| van Eggermond et al. | Transcriptional silencing of RFXAP in MHC class II-deficiency | |
| Maier et al. | Identification of a distal tandem STAT6 element within the CCL17 locus | |
| Yu et al. | Characterization of the promoter of human leukocyte-specific transcript 1: a small gene with a complex pattern of alternative transcripts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060217 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090331 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090618 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090625 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090721 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090728 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091006 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091221 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100104 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100406 |